Background: Ischemia reperfusion injury is a barrier to liver surgery and transplantation, particularly for steatotic livers. The purpose of this study was to determine if pretreatment with a single dose of intravenous fish oil decreases hepatic ischemia reperfusion injury and improves recovery of injured livers.
occluded temporarily to limit blood loss. IRI is particularly problematic in steatotic livers, limiting their use as donor organs. 1, 2 Clinical evidence of IRI includes remnant liver dysfunction after resection or donation and early allograft dysfunction or primary nonfunction after liver transplantation. Primary nonfunction necessitates urgent retransplantation in up to 10% of patients; early allograft dysfunction, which occurs in up to 25% of patients is associated with an increased incidence of rejection. [3] [4] [5] [6] Fish oil lipid emulsion rich in anti-inflammatory omega-3 fatty acids (O3FA) and the antioxidant α-tocophero may play a role in preventing or ameliorating IRI. 7, 8 Intravenous fish oil (IVFO) decreases inflammatory and oxidative insults in intestinal failureassociated liver disease, and long-term oral fish oil supplementation may decrease steatosis in nonalcoholic fatty liver disease. [9] [10] [11] [12] [13] The role of IVFO in decreasing IRI when given before liver surgery and transplantation, however, is unknown. study was to determine if pretreatment with a single dose of IVFO can decrease hepatic IRI and improve recovery of the injured livers in a murine model.
Methods

Animal model and surgery
Experimental protocols were approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital. Only male mice were used to eliminate sex as a potentially confounding variable. Sixty 6-to 8-week-old, C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) received 1g/kg of IVFO ( n = 30; Omegaven; Fresenius Kabi, Bad Homburg, Germany) or isovolumetric 0.9% NaCl (saline; n = 30) via tail vein injection. The IVFO dose of 1 g/kg was chosen after a lesser dose (0.2 g/kg) was found to be ineffective. This dose has been used clinically for over a decade in children with a well-demonstrated safety profile. 10 One hour later, mice were anesthetized with inhaled isoflurane for IRI procedure. After upper midline laparotomy, the portal triads to the cephalad liver lobes were dissected free to allow for suture ligature/occlusion with a 4-0 PDS (Ethicon, Somerville, NJ) weighted with a straight snap placed at a 45-degree angle to the mouse's long axis. Ischemia was confirmed visually as the cephalad lobes promptly turned gray. After 30 minutes of ischemia, suture ligatures were removed, reperfusion was confirmed visually as the previously gray lobes became red, and the abdomens were closed. The ischemia time of 30 minutes was chosen after a greater time (60 minutes) was found to produce near-complete necrosis with no viable liver to salvage.
After 4 ( n = 20), 8 ( n = 20), or 24 ( n = 20) hours of reperfusion, mice were killed by carbon dioxide inhalation. Blood was collected immediately from the inferior vena cava, and livers, spleens, and right kidneys were procured.
Serum analysis
Whole blood was centrifuged at 2,348 g at 4 °C for 18 minutes. Serum was aspirated into a new tube and stored at −80 °C. Serum levels of alanine transaminase (ALT) were measured by the Boston Children's Hospital clinical laboratory.
Liver analysis
Livers were weighed and then placed in anatomic position for isolation and orientation of the cephalad lobes that had been exposed to IRI. To prevent potential bias from choosing liver segments for histologic analysis based on gross appearance, specimen collection was standardized. The lateral half of the left lateral lobe (cut diagonally) and inferior half of the right medial lobe (cut transversely) were marked medially with yellow pathology paint and inferiorly with black paint (Davidson Marking System; Bradley Products, Bloomington, MN), fixed in 10% formalin, and paraffin embedded. 14 Formalin-fixed, paraffin-embedded liver specimens were stained with hematoxylin and eosin (H&E) by the clinical pathology department for cross-sectional microscopic analysis of hepatic architecture by a blinded, board-certified pathologist. Livers procured 8 hours after reperfusion also were stained with Ki67 to quantify proliferating hepatocytes. Starting at a distance of 1 high-powered field (HPF, 400 × magnification) from the edge of the specimen, Ki67-stained hepatocytes were counted in a blinded fashion across each specimen for every other row and reported as number of Ki67-positive hepatocytes per 10 HPFs. Hematoxylin and eosin slides for livers procured 24 hours after reperfusion were assessed in a blinded fashion to determine the percentage of necrosis per area using ImageJ software (National Institutes of Health, Bethesda, MD). Percent necrosis was calculated for each lobe for consecutive fields at 100 × magnification across the middle of the specimen starting at the yellow painted edge and for the lobe as a whole at 20 × magnification.
Statistical analysis
Preoperative weights, organ weights as a percentage of preeuthanasia body weights, and serum ALT among the 6 groups were analyzed using 2-way analysis of variance (ANOVA) with factors for time of sacrifice (4, 8, or 24 hours postreperfusion), treatment group (saline or IVFO), and their interaction. Percent change in weight from preoperative weight to pre-euthanasia weight was analyzed using analysis of covariance, where outcome was regressed on the time of death, treatment group, and their interaction, and adjusted for preoperative weight. The comparison of group means at 4, 8, and 24 hours of reperfusion were adjusted for multiple comparisons using the method of Holm. 15 Ki67 (Ki67-positive hepatocytes/10 HPF) and necrosis (percent of necrosis per area, both as a line across and for lobe as a whole) were analyzed at 8 and 24 hours postreperfusion, respectively, with a repeated-measures mixed model ANOVA. A compoundsymmetric covariance matrix was used to model the within-mouse correlation between right and left lobes.
ALT, Ki67, and necrosis were right-skewed. ALT and necrosis were log-normal, while Ki67 required transformation to normal scores calculated from the ranked data as
where Ф −1 is the inverse cumulative normal function, r i is the rank of the i th observation, and n is the number of observations. 16 Results for ALT and necrosis were back-transformed to their original scales by exponentiation. Mixed model results for Ki67 normal scores were consistent with analysis on the original scale, and only the latter are reported.
All results are reported as mean with 95% confidence interval (CI). Tests of significance are two-sided. Data were analyzed using SAS version 9.4 (Cary, NC), and GraphPad Prism 7.0 (La Jolla, CA).
Results
Animal and organ weights
There were no differences in preoperative body weight among the 6 groups ( n = 10/group, P = . 53, data not shown). There were, however, differences in percent change in body weight from preoperative to pre-euthanasia weight among the 6 groups ( P = . 03). At 4 hours after reperfusion, IVFO-treated mice experienced a mean decrease of −0.9% (95% CI, −2.3 to 0.6) body weight, while salinetreated mice experienced a mean increase of 1.6% (95% CI, 0.1-3.1) body weight ( P = . 04). At 8 hours after reperfusion, IVFOtreated mice lost more weight on average than saline-treated mice (IVFO −4.9%; 95% CI, −6.4 to −3.4) versus saline ( −1.7%; 95% CI, −3.2 to −0.2; P = . 01). At 24 hours after reperfusion, there was no difference in weight loss between mice who received IVFO and those who received saline ( P = . 54), with mice in both groups experiencing an average decrease of −6.7% (95% CI, −7.7 to −5.7) from their preoperative weight. There were no differences in liver, right kidney, or spleen weights as a percentage of pre-euthanasia body weights among the 6 groups ( Fig 1 ; P liver = 0.58, P kidney = 0.11, P splee n = 0.12).
Serum ALT
At 4 hours after reperfusion, there was no difference in serum ALT between mice that received saline and those that received IVFO prior to IRI ( Fig 2 ) . At 8 hours after reperfusion, IVFO-treated Fig. 1. ( A ) Liver, ( B ) right kidney, and ( C ) spleen weight as a percentage of pre-euthanasia body weight for mice treated with 0.9% NaCl (saline) or IVFO prior to IRI and killed 4, 8, or 24 hours after reperfusion ( n = 10/group). There were no differences among the groups (liver P = . 58, kidney P = . 11, spleen P = . 12). Shown are mean (95% CI). P values are from ANOVA. mice had lesser values of serum ALT on average than saline-treated mice (IVFO 1806 IU/L (95% CI, 1,398-2,335) vs saline 5451 IU/L (95% CI, 4,218-7,045; P = . 01). There was no statistical difference in serum ALT between IVFO-and saline-treated mice at 24 hours after reperfusion.
Histologic analysis
Livers from saline-treated mice killed 4 hours after reperfusion demonstrated marked ischemia diffusely around the central veins with some scattered cells and areas of necrosis consistent with early ischemia ( Fig 3 ) . Livers from IVFO-treated mice killed 4 hours after reperfusion demonstrated small scattered foci of necrosis that were not limited to the areas surrounding central veins, with normal liver between areas of necrosis. Some regenerating hepatocytes also were seen.
After 8 hours of reperfusion, both saline-and IVFO-treated livers demonstrated pale areas of cell loss with surrounding regenerating hepatocytes. It appeared there were more regenerating cells around areas of necrosis in IVFO-treated livers compared to saline-treated mice, which was confirmed with Ki67 staining ( Fig 4 ) . There were on average 22. After 24 hours of reperfusion, both saline-and IVFO-treated livers demonstrated patchy areas of frank necrosis and normalappearing liver without preference for central vein or periportal space. There was significantly less necrosis in the livers of mice that received IVFO prior to IRI compared to mice that received saline ( Fig 5 ) . Calculated for consecutive fields across the middle of the specimens, there was on average 1.3% (95% CI, 1.0-1.6) necrosis in IVFO-treated livers compared to 9.6% (95% CI, 7.7-11.9) necrosis in saline-treated livers ( n = 10/group; P < .0 0 01). Calculated for the entire specimens, there was on average 0.8% (95% CI, 0.6-1.0) necrosis in IVFO-treated livers compared to 7.8% (95% CI, 6.2-9.8) necrosis in saline-treated livers ( n = 10/group; P < .0 0 01). 
Discussion
Despite major improvements in liver surgery and transplantation and in pre-and postoperative care, hepatic IRI remains an important complication. Steatotic livers are particularly sensitive to IRI, which increases morbidity and mortality after major hepatic resections and limits their use are donor organs. 1, 2, 17 Our study demonstrates that pretreatment with a single dose of IVFO increased hepatocyte proliferation and decreased the extent of necrosis in a murine model.
Our results are consistent with the results of Raptis et al, who reported decreased necrosis at 24 hours post-IRI in mice pretreated with IVFO. 7 These findings also support the work of Linecker et al, who showed increased Ki67 positivity after major hepatectomy in steatotic mice pretreated with IVFO. 8 Our results differ from these prior studies in that the present study describes a temporal progression of histologic findings suggesting that in IVFO-treated mice, injury still occurs but is associated with increased regeneration and decreased necrosis over time.
The underlying mechanism for the observed decrease in hepatic injury and increased cellular regeneration remains unclear, and further mechanistic explanations are pending further experimentation. The O3FA eicosapentaenoic acid and docosahexaenoic acid are precursors to anti-inflammatory prostaglandins and leukotrienes and to specialized proresolving mediators. 18 O3FA agonism of free fatty acid receptor 4 (also known as GPR120) in Kupffer cells suppresses NF κB-mediated inflammatory pathways. 19 Given this knowledge, it is possible that IVFO accelerates recovery from hepatic IRI through attenuated release of inflammatory mediators. 7 O3FA-derived, proresolving mediators may also accelerate the transition from injury to repair, allowing cells not directly injured to return to normal function sooner, and cells around injured cells to begin the recovery process sooner. A single bolus of IVFO given 1 hour before ischemia is unlikely to change cellular membrane composition. One study by Kasuga et al, however, demonstrated that circulating O3FA as opposed to cell membrane released O3FA accumulate quickly in inflammatory exudates. 20 They further demonstrated that administration of the O3FA-derived resolvin RvD1 was able to decrease pulmonary neutrophil infiltration just 2 hours after hind limb IRI.
While it would be difficult to prove the difference between the effects of the anti-inflammatory and proresolving pathways, because they are undoubtedly intertwined, there are important clinical implications to these findings. It is not always possible to prevent injury, but if liver healing and regeneration can be accelerated, it may be possible to improve patient outcomes. IVFO could be administered before or during liver surgery when other preemptive measures to decrease IRI (such as dietary changes or oral O3FA supplementation to decrease steatosis) or to increase healthy remnant liver (such as portal vein embolization) are not feasible. That IVFO accelerates regeneration after IRI may help explain the findings of Zhu et al and Zhang et al, who reported improved outcomes in patients receiving O3FA-enriched parenteral nutrition after liver transplantation and hepatic resection, respectively. 21, 22 A limitation of this study is the attribution of the hepatoprotective effects of IVFO to O3FA rather than to the antioxidant α-tocopherol. The data on whether α-tocopherol is able to decrease hepatic IRI is somewhat conflicting, 7, 23 but the potential synergistic effect between α-tocopherol and O3FA cannot be overlooked. The production of IVFO requires α-tocopherol; therefore, lipid emulsions with added α-tocopherol would be needed to discriminate with any confidence the effects of these 2 components. In addition, the effect of dose-response and duration of ischemia were not fully explored in this study. The IVFO dose of 1 g/kg was chosen because this is used clinically in parenteral nutrition-dependent children receiving IVFO for treatment of intestinal failure-associated liver disease; however, a greater dose may have a more profound effect, and dose-response studies with associated toxicity analysis and testing of coagulation parameters will be necessary before any clinical use can be considered. In summary, this study demonstrates that a single dose of 1 g/kg IVFO given before hepatic IRI results in increased hepatocyte regeneration and decreased necrosis in murine livers. Given the safety profile of IVFO, these findings have the potential to be translated into preventative and treatment strategies for IRI in liver surgery and transplantation. Further studies are needed to determine the mechanism of this protection.
